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Background/aim: Recently, a novel circulatory system, the primo vascular system (PVS), was
found to be a potent metastatic route of cancer cells. The aim of the current work is to demon-
strate that cancer cells injected into the testis migrate through the primo vessel (PV).
Materials and methods: NCI-H460 cells labeled with fluorescent nanoparticles (FNP) or green
fluorescent protein (GFP) gene transfection were injected into testicular parenchyma in 24
rats. After 24 hours of injection, the abdominal cavity was investigated via a stereomicro-
scope, to detect the PVS, and the samples were analyzed histologically with 40,6-diamidino-
2-phenylindole (DAPI) and hematoxylin and eosin.of Acupuncture and Moxibustion, Wonkwang University Hospital, Gwangju, South Korea.
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testisResults: Injected cancer cells were detected inside the PVS distributed on the abdominal or-
gans. Some were detected inside intestinal parenchyma into which the attached primo vessels
(PVs) entered.
Conclusion: The results supported the fact that the PVS may be a novel migration path of can-
cer cells, in addition to the lymphatic and hematogenous routes.1. Introduction
Testicular cancer is one of the most common solid tumors in
young adults, and it requires appropriate management at
all stages [1e3]. The dreadful metastasis of this tumor was
thought to be through the lymph vessels and imaging of
lymph nodes has been widely pursued for identifying the
most likely sites of metastatic disease [4e7]. This emphasis
in lymphatic metastasis is based upon the conventional
knowledge that cancer metastasis routes are only blood and
lymphatic vessels, or movement within body cavities [5].
However, metastasis via blood or lymphatic vessels is not
enough to explain the high rate of cancer metastasis,
because several host defense mechanisms protect the body
from the cancer by interrupting the migration of cancer
cells via blood or lymphatic vessels. For example, most
cancer cells could be destroyed in transit through blood and
lymphatic vessels. There are several reports of the in-
efficiency of the metastatic route via blood and lymphatic
vessels; 99% of melanoma cells injected into a blood stream
are destroyed within 24 hours and 0.1% of mammary cancer
cells can be observed in the blood even though mammary
cancer can shed one million cells a day [8]. Also, sup-
pressing angiogenesis and lymphangiogenesis are not al-
ways effective methods for cancer treatment. In theory,
cancer treatment to suppress blood and lymphatic metas-
tasis is supposed to be effective; in practice, however,
metastasis often develops, even when aggressive treatment
suppressing blood and lymphatic metastasis is offered to
patients.
Therefore, there is a need to find other mechanisms of
cancer metastasis, in particular, anatomical structures as a
cancer metastatic route. First, a novel structure related to
cancer metastasis, so-called vasculogenic mimicry, was
discovered. It is a formation of matrix-rich vessel-like
networks by highly aggressive tumor cells, such as: mela-
nomas; breast, prostate, ovarian, chorion, and lung carci-
nomas; synovial sarcoma, rhabdomyosarcoma, and Ewing
sarcoma; and pheochromocytoma [9e12]. In these aggres-
sive tumor tissues, tumor cells are undifferentiated,
embryonic-like phenotype. In particular, several signaling
molecules related to embryonic vasculogenesis, such as
vascular endothelial cadherin, regulate the vasculogenic
mimicry and their endothelial-like phenotype in a mela-
noma [10e13]. This novel structure has fluid-conducting
sinusoids for microcirculation; it could therefore be help-
ful to prevent tumor necrosis, and work for additional
metastatic routes by offering tumor perfusion and nutri-
tional exchange [10e12,14].
As another novel anatomical structure, the primo
vascular system (PVS) was offered as a potent metastatic
path [15e17]. The PVS is a vascular threadlike structure,consisting of primo vessels (PVs) and nodes, which forms a
network all over the body including organ surfaces, inside
blood and lymphatic vessels, central canal spinal cord, and
ventricles [18,19]. Its anatomical and histological struc-
tures were distinctively different from other established
structures, including blood and lymphatic vessels, or nerves
[20]. The PVS has its own circulating fluid and very small
microcells that contain DNA [15,21,22]. A cancer-
associated PVS was first observed on the fascia surround-
ing superficial tumors [16] and it was additionally
confirmed, using in vivo visualization by a multispectral
imaging system, for cancer cells labeled with quantum
dots, that cancer cells preferentially migrated via the PVS
from implanted original tumors to metastatic tumors in
xenograft mouse models [17].
Subsequently, independent observations of cancer-
associated PVS were followed by other groups. With female
Swiss Webster mice, Akers et al observed the PVS loosely
attached to the surface of the tumor which was grown in
mouse skin by inoculation of mouse mammary carcinoma
cells suspended in PBS in the right flanks subcutaneously
[23]. A PVS attached to the fascia surrounding a tumor tissue
in a murine melanoma model was reported [24]. Another
experiment, with a green fluorescent protein (GFP)
expressing mouse, showed strong formation of PVs on the
tumor that coexisted with blood vessels and expressed GFP.
The result suggested that the PVS of an induced melanoma
tumor developed endogenously from the host body [25].
The purpose of the current study is to confirm the
migration of the cancer cells via PVs after cancer cell in-
jection. As an injection point, we selected bilateral testic-
ular parenchyma, because the PVS connected to the testis
was previously investigated, and the results showed that
dyes flowed in PVs after intratesticular injection of the dye.
For visualization of the cancer cells, fluorescent nano-
particles (FNP)-labeled or GFP expressing cancer cells were
injected and observed by multiphoton microscopy. Our hy-
pothesis was that the injected cancer cells could migrate via
the PVS from the testis after intratesticular injection. If this
hypothesis is proven, it would strongly suggest that the
cancer cells could arrive at other organs from the testis and
this could be a metastasis route of testicular cancers, which
is themost common solid tumor in young adults and is rising in
both the United States and Europe [1e4].2. Materials and methods
2.1. Cell lines
The cell line NCI-H460 was provided by the Korean Cell
Line Bank (Seoul, Korea). Human lung cancer cells were
300 H.-J. Han et al.subcultured in an RPMI-1640 medium supplemented with 1%
penicillin-streptomycin and 10% fetal bovine serum (FBS)
purchased from Invitrogen (New York, NY, USA). Cells were
incubated at 37 C in a humidified atmosphere containing
5% CO2.
2.2. Cell labeling with FNP
A suspension of FNP was synthesized following previous
studies that employed a modified polyvinylpyrrolidone
method. Cobalt-ferrite magnetic nanoparticles coated with
a shell of amorphous silica were synthesized [26,27]. A
luminescent organic dye, rhodamine B isothiocyanate [RITC,
orange, lmax (em)Z 555 nm], was inside the silica shell and
biocompatible poly(ethylene glycol) (PEG) was on the
outside. The average size of the water-soluble bare cobalt-
ferrite magnetic nanoparticles was 9 nm. The average total
size of the core-shell structurewas 50 nm. The concentration
of nanoparticles was 10 mg/mL in PBS at pH7.4.
The cancer cells were labeled with FNP by the electro-
poration method, which used an electrical pulse to per-
meabilize the phospholipid bilayer of the plasma
membrane. The electrical pulse resulted in the formation
of a very high reverse membrane potential and the FNP
were delivered into the cells. The electroporation method
was implemented with equipment consisting of a high-
voltage pulse generator and microchip applicator (Solco
Biomedical Co., Seoul, Korea). The optimal conditions
for the intracellular delivery with the electroporation
method were: pulse width Z 100 mseconds, pulse
interval Z 100 mseconds, number of pulses Z 18, pulse
amplitudes Z 1.3 kV/cm, and pulse shape Z square wave
[17].
2.3. Transfection and expression of GFP cells
For GFP gene transfection in the NCI-H460 cells, the Lip-
ofectamine 2000 (Invitrogen) transfection was carried out
following the general protocol (Invitrogen Lipofectamine
2000 technical manual, see the Supporting Information for
our particular procedure) and a previous study [28]. The
cell sorter (BD FACSAria III; BD Diagnostics Systems, Sparks,
MD, USA) was used to isolate only GFP-expressed-cells from
the cultured cells.
2.4. Animal preparation
Male Sprague Dawley rats were used in this study. They
ranged from 8 weeks to 10 weeks in age, and their body
weights ranged from 150 g to 250 g. The animals were
housed in a temperature-controlled environment (23 C)
with 60% relative humidity and a 12 hour light/dark cycle.
They had ad-libitum access to food and water. To suppress
the immune function of the rats, 25 mg/kg of cyclosporin A
was injected intramuscularly into the hind leg daily, on 3
consecutive days before cancer cell inoculation. The pro-
tocol of immunosuppression was based on Goodman and
others’ reports [29,30].
The procedures involving the animals and their care
were in full compliance with current international laws and
policies (Guide for the Care and Use of Laboratory Animals,National Academy Press, 1996). The study design and
experimental protocols were approved by the Institute of
Laboratory Animal Resources of Seoul National University.
2.5. Intratesticular inoculation of FNP-labeled or
GFP expressing NCI-H460 cells
Under general anesthesia (xylazine 10 mg/kg, plus keta-
mine 70 mg/kg, intramuscular injection), bilateral testes of
the rats were inoculated with approximately 1  107 FNP-
labeled NCI-H460 cells resuspended in 100 mL of RPMI-
1640, using a 26-gauge needle attached to a 1 mL plastic
disposable syringe, after centrifugation. In GFP-expressed-
cells, the same procedure was also followed, after har-
vesting the cells with trypsin. The cancer cells were
injected into the testicular parenchyma.
2.6. Intraoperative imaging
In order to identify the PVS inside the abdominal cavity, we
performed a laparotomy on rats at 24 hours after inocula-
tion of NCI-H460 cells, under euthanization using ether. The
midline of the rat abdomen was incised without hemor-
rhage and the abdominal organs were exposed carefully. All
operative procedures were performed under a stereomi-
croscope (SZX12; Olympus, Tokyo, Japan), and the images
were taken with a CCD camera (DP 70, Olympus).
2.7. Microscopy and histological analyses
The fluorescence intensity and distribution of FNP-labeled
and GFP cells were confirmed by multiphoton microscopy.
For multiphoton microscopic observations, the transfected
cells were fixed in 4% paraformaldehyde for 29 minutes,
washed in PBS several times, mounted with anti-fade re-
agents, and imaged using an LSM 510 META multiphoton
microscope (Zeiss, Oberkochen, Germany). In particular,
FNP-labeled cells were separated by the centrifugal sepa-
rator and then washed out by PBS 1  after cell labeling
using the electroporation method. This procedure resulted
in removing the remaining FNP that were not delivered into
the cells. Then, the nuclei were labeled with 40,6-
diamidino-2-phenylindole (DAPI; Molecular probes,
Eugene, OR, USA).
After taking samples of the PVS, anex vivo re-examination
was performed with a multiphoton microscope (LSM 510
META; Zeiss) or an optical microscope (BX 51; Olympus). For
this purpose, the samples were counterstained with DAPI.
Selected samples were sectioned at 5 mm and were stained
with hematoxylin and eosin (H&E) staining to identify the
histological characteristics of the PVS.
3. Results
3.1. Validation of cell labeling
FNP were effectively penetrated into the H460 cells after
electroporation (Fig. 1A). They were distributed in both
cytoplasm and nuclei, but most FNP penetrated into cells
were located in cytoplasm rather than nuclei.
Figure 1 Validation of fluorescence-labeled human lung cancer cells (NCI-H460) by nanoparticles or green fluorescent protein
(GFP). Fluorescence and differential interference contrast (DIC) micrographs of those cells are shown: (A) fluorescent nano-
particles (FNP)-labeled NCI-H460 cells; red fluorescence: FNP, blue fluorescence: 40,6-diamidino-2-phenylindole (DAPI) depicting
nuclei; and (B) GFP expressed NCI-H460 cells (bar: 20 mm).
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clones in the levels up to 800 mg/mL of G418. The selected
G418-resistant H460-GFP cells had bright GFP fluorescence
(Fig. 1B). The cell proliferation rate of the GFP expressed
cells was much lower than that of the parental cells, as
measured by comparing their doubling times in vitro. This
caused in time an increase of the relative population of the
unexpressed cells in the culture well plates of mixed pop-
ulation. Thus, it was necessary to use the cell sorter to
isolate only the GFP cells to form the population of pure
GFP cells.
3.2. In vivo observation of the PVS in abdominal
cavity by laparotomy
The PVs were distributed on the surfaces of abdominal or-
gans, including abdominal wall, liver, spleen, intestines,
urinary bladder, and prostate gland (Fig. 2). They were thin,
semitransparent, flexible, and freelymovable. The diameter
of the PVs ranged from 30 mm to 50 mm, and linked to the
primo nodes, which were also semitransparent with sizes of
about 500 mm  200 mm. Some of the PVs were divided into
several branches or merged, and formed the network on the
surface of the internal organs in the abdominal cavity.
Several PVs were linked to the great omentum and adjacent
visceral peritoneum. In addition, some entered the paren-
chyma of the small intestine (Fig. 3D).
3.3. Migration of FNP-labeled or GFP expressing
cancer cells via PVs in abdominal cavity
FNP-labeled or GFP expressing cells were detected inside
PVs and primo nodes distributed on the surfaces of
abdominal organs by multiphoton microscopy (Fig. 3). PVswere identified with rod-shaped nuclei with lengths of
about 10 mm, which were arranged in a broken-line striped
fashion. This characteristic feature is consistent with pre-
vious observations of PVs (Fig. 3B and H). Inside the PVs and
primo nodes, cells emitting strong fluorescence of FNP were
observed (Fig. 3B, C, and E).
In the case of intratesticular inoculation of GFP
expressing cells, cells with GFP fluorescence were also
detected inside the PVS (Fig. 3H and I). In particular, GFP
expressing cells were detected inside intestinal paren-
chyma into which the attached PVs entered (Fig. 3F).
3.4. Comparison of PVs and lymphatic vessels after
intratesticular inoculation of cancer cells
PVs have similar gross features, such as color, semi-
transparency, and size to lymphatic vessels, although PVs are
freely movable, while lymphatic vessels are fixed to a peri-
toneum (Fig. 4A). However, their histological structures
were distinctively different from lymphatic vessels (Fig. 4C).
The most prominent point for discrimination is that the PV is
of a cribriform structure consisting of numerous micro-
sinuses surrounded by collagen fibers and cells, while the
lymphatic vessel is of a single lumen structure without
matrixes filling the lumen. Some cells were floating inside
micro-sinuses in the PVs. In addition, fluorescence of FNP-
labeled cells was detected in PVs, while there was no fluo-
rescence of FNP in a lymphatic vessel after intratesticular
inoculation of the cancer cells (Fig. 4B).
4. Discussion
Recently, Yoo et al reported that PVS were developed
around tumors [16,19], and cancer cells migrated via PVs
Figure 2 Primo vascular system forming the network in the abdominal cavity. Primo vessels (PVs) are distributed over the
abdominal organs branching out or putting together. Some PVs linked to primo nodes (black arrowheads) and merged into a visceral
peritoneum (white arrows).
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therefore, this could be a potent route for metastasis, in
addition to blood and lymphatic vessels, in a mouse model
[17]. We studied the possibility of the PVS as a metastatic
route in a rat model through observation of cancer cell
migration after 24 hours from intratesticular injection of
cancer cells. The choice of testis for the study was moti-
vated by our previous study, in which the intratesticular
injected dye flowed through the PVS in the abdominal
cavity toward other organs [31]. Therefore, we hypothe-
sized that cancer cells injected into the testis could also
move through the PVS. In the current work, we confirmed
that cancer cells migrated via the PVS after intratesticular
injection. Under multiphoton microscopy, fluorescent-
labeled cancer cells were observed in many PVs
emanating from the testis. In particular, several cancer
cells were observed in the small intestine to which a PV
from the testis was linked. The injected cancer cells in the
testis migrated via a PV and they entered the intestinal
parenchyma through the PV. An important issue is whether
these cancer cells can grow there and metastasis occurs.
This remains to be tested in the future.
We were particularly concerned to distinguish the PVS
from the lymphatic system, because of their similarity inanatomical appearance and physiological function, as a
route of metastasis. The histological differences between
themwere illustrated in Fig. 4.With regards to the functional
aspects, we noticed that the speed of flow is important in
distinguishing between them. The speed of primo fluid is
slower than that of lymph; the primo fluid speed is
0.3  0.1 mm/second while the lymph speed has an average
of 0.87 0.18 mm/second and peaks of 2.2e9.0 mm/second
in rats, even though it varies with the phasic contractions in
both direction and magnitude [21,32]. The lower speed of
the primo fluid makes the moving cancer cells easily attach
the abundant collagen matrices surrounding sinuses of PVs.
By contrast, cancer cells cannot easily remain in lymphatic
vessel walls, because of the rapid flow velocity, and they
cannot flowuntil they finally reach a lymph node,where they
can grow [33,34]. In the current study, fluorescent tumor
cells were observed in the PVs, but those cells were not
detected inside lymphatic vessels. This does not mean that
cancer cells did not migrate through lymph vessels; it simply
implies that cancer cellsmoved away from the injection area
in less than 24 hours, because we observed the presence of
cancer cells 24 hours after injection. This was one of our
limitations due to the lack of a real time tracing of cancer
cells in the body.
Figure 3 Migration of fluorescent nanoparticles (FNP)-labeled or green fluorescent protein (GFP) expressing cancer cells via the
primo system into a certain organ parenchyma after intratesticular inoculation. (A) A stereoscopic image showing three branches of
primo vessels (PVs, black arrow) linked to the primo node (white arrow); (B) observation of PVs; (C) observation of the primo node
in picture (A) using multiphoton microscopy. There were FNP-labeled cells inside the primo vascular system. Each right image is the
magnification view of the left one; (D) a primo node and attached PV (white arrowhead) entered into the intestinal parenchyma
(black arrowhead); (E) and (F) FNP-labeled cells were detected inside not only PV and a node (E; white arrowhead in picture D) but
also intestinal parenchyma (F; black arrowhead in picture D) into which PVs entered. Each right image is the magnification view of
the left one; (G) a primo node (black open arrow) and linked PV (white open arrows); (H) and (I) GFP expressing cells were shown in
a PV (H) and a primo node (I) from picture (G). Each right image is the magnification view of the left one (fluorescence of red: FNP,
blue: 40,6-diamidino-2-phenylindole (DAPI) depicting nuclei, green: GFP).
Figure 4 Comparison between a primo vessel (PV) and a lymphatic vessel after intratesticular inoculation of fluorescent
nanoparticles (FNP)-labeled or green fluorescent protein (GFP) expressing cancer cells. (A) Stereoscopic image of a PV (black
arrow) and a lymphatic vessel (white arrow). Gross feature of a PV is similar to a lymphatic vessel; (B) investigation of fluorescence
of FNP-labeled cells under phase contrast microscopy. In a PV, there are numerous instances of fluorescence from FNP-labeled
cells, while there is no fluorescence in a lymphatic vessel; (C) sections of a PV (oblique section of coiled PV) and a lymphatic
vessel (cross section) stained with hematoxylin and eosin (H&E). A PV is a multi-sinuses structure (white arrows) with floating cells
(asterisks) surrounded by collagen fiber, while a lymphatic vessel is clearly of a single lumen structure.
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besides the above mentioned fluid speed. Another possible
reason is the abundant collagen matrix of PVs. A PV has a
cribriform structure consisting of abundant collagen fibers,
contrary to a lymphatic vessel. This matrix could be another
migration route of cancer cells, in addition to migration via
sinuses in PVs, because cancer cells are slowly migrated via
extracellular matrix using reorganization of the matrix by
drawing at attachment sites, limited fiber disruption, and
the shedding of cell surface determinants, especially acting
on beta-1-integrin-mediated adhesion [35].
The results of the current study suggest that PVs could
provide two cancer cell migration mechanisms: intrasinus
flowing and/or extrasinus movement through matrix with
collagen fibers. It is the major limitation of the current
investigation that we could not clearly delineate the two
migration paths to determine the exact track. Further study
with real time tracing of cancer cells would be worthwhile.
FNP were used originally for stem cell labeling to be
detected byMRI [36,37] and then developed for use in cancer
cell labeling [38]. The advantage of the use of FNP is that it is
a noninvasive method for monitoring cell implantation. FNP-
labeled cells could be implanted in vivowithout any harmful
effect to the living body, for tracing the whole movement
path [38]. In particular, a cell-labeling technique using
exogenous fluorescent probes induces those fluorescent
materials to enter into the target cells via endocytosis or
electroporation, so that there is no adverse effect caused by
cell transfection of endogenous fluorescent proteins, which
have been commonly used for cell labeling [5,39]. With
minimal invasive properties, the amount of fluorescence is
similar to the cell labeling technique using endogenous
fluorescent proteins [40]. Another advantage of using la-
beling with exogenous fluorescent probes is its compara-
tively easy, rapid, and simple technique to induce cell
labeling [5]. In particular, cell labeling using electroporation
provide less harmful chemical effects, with more exact
control of efficacy for cell labeling, as it has concentration-
dependent characteristics [5,41].
We used FNP-labeled cells using electroporation to
detect injected cancer cells in in-vivo samples. Using this
technique, cell labeling was performed safely and easily,
providing even delivery of FNP into the cells. There were no
released independent FNP in the extracellular matrix,
which can result in false-positive detection of cancer cells.
In the case of cancer cell labeling with FNP, the duration of
FNP-labeled cells should be considered, in that division of
intracellular FNP occurs rapidly, because cancer cells pro-
liferate rapidly [38,42]. It is important to estimate the
duration that FNP could be detected in labeled cancer
cells, because FNP division resulting from cell division
might cause weakening of fluorescent intensity, inducing
false-negative detection [5]. However, we did not need to
consider the duration of FNP division herein, because we
focused on detecting FNP-labeled cells for a period of 24
hours. Based on the preliminary study, significant changes
of fluorescent intensity of FNP inside cells did not occur
within 24 hours. In the current study, FNP-labeled cells
showed a strong intensity of fluorescence, which was
enough to observe those cells inside in vivo samples.
When it comes to using FNP-labeled cells, there is an
important shortcoming that FNP inside cancer cells couldbe delivered into immune cells, such as macrophages,
which phagocytize FNP-labeled cells. This could result in
serious errors of the outcome, in that immune cells showing
FNP by phagocytizing FNP-labeled cells might be mis-
interpreted as FNP-labeled cancer cells. This problem was
overcome by using GFP expressing cancer cells, which is
known to be one of the most effective cell labeling
methods. Macrophages that phagocytized GFP cancer cells
do not produce this kind of misinterpretation, because they
do not show any green fluorescence. In the current study,
we obtained consistent results both with the FNP-labeled
cells and GFP expressing cells. That is, the fluorescent cells
in the PVS after intratesticular injection were original
cancer cells which had migrated from the testis.
There were several limitations that require further
investigation in future. The real time observation of the
movements of cancer cells was not possible. Precise and
detailed anatomical description of the emerging point of
the PV from the testis was not possible, because we could
not trace the PV through the fat tissue around the testis. It
was not possible to observe growth of cancer cells in the
internal organs where they moved to in the current
program.
In conclusion, FNP-labeled and GFP expressing cancer
cells were detected in PVS starting from the testis and
parenchyma of internal organs which are connected to the
PVS after 24 hours of intratesticular injection of those cells.
The outcome showed that the cancer cells could migrate
through PVs and thus suggested the PVS an extra metastatic
path besides the lymphatic one.
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